About iPROLEPSIS

 

Psoriatic Arthritis (PsA) is a chronic, progressive, inflammatory disease affecting 1-2% of the general population, while manifesting in up to 30% of people with psoriasis (PsO).

​

 

 iPROLEPSIS OBJECTIVES:

• Discover PsA inflammation drivers through AI-driven health, environmental and omics data mining

• Develop and validate objective digital biomarkers for tracking inflammatory symptoms and disease activity

• Investigate the role of mast cells and features from non-invasive skin microvascular/joint imaging in inflammatory symptoms tracking

• Build trustworthy AI models for personalised PsA risk prediction, early diagnosis and high disease activity prognosis

• Develop ICT-based personalised interventions to sustain or even improve quality-of-life

• Develop and clinically validate the iPROLEPSIS digital health ecosystem to empower persons with/at risk of PsA and healthcare professionals

• Co-create the iPROLEPSIS ecosystem with key stakeholders, following ethical, inclusive and trustworthy AI principles

 

​

GENERAL INFORMATION:

Duration: 48 months

Start and end date: 2023 01 01 – 2026 12 31

Number of partners: 14

Total budget: € 6.48M

​